Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™
USA - English
Share this article
Share this article
YOKNE AM ILLIT, Israel, April 29, 2021 /PRNewswire/ Lumenis Ltd., the world s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD).
Dry eye disease is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision. About 16 million Americans have been diagnosed,